Sex differences in effectiveness of first-line tumor necrosis factor inhibitors in axial spondyloarthritis; results from fifteen countries in the EUROSPA Research Collaboration Network
14/08/2023
P. Hellamand1 , M. G. H. Van de Sande2 , L. Midtbøll Ørnbjerg3 , T. Klausch4 , M. Nurmohamed5 , R. Van Vollenhoven6,7, D. Nordström8 , A. M. Hokkanen9 , M. J. Santos10, E. Vieira-Sousa11, A. G. Loft12,13, B. Glintborg3 , M. Østergaard3,14, U. Lindström15, J. K. Wallman16, B. Michelsen3,17,18, A. Ciurea19, M. J. Nissen20, C. Codreanu21, C. Mogosan21, G. Macfarlane22, G. T. Jones22, K. Laas23, Z. Rotar24,25, M. Tomsic24,25, I. Castrejon26, M. Pombo-Suarez27, B. Gudbjornsson28,29, A. J. Geirsson30
EULAR 2022
DOI: 10.1136/annrheumdis-2022-eular.2837
https://ard.bmj.com/content/81/Suppl_1/13